FDA Keeping Eye on Online Drug, Device Benefit Promises

imgMitchellParish

Mitchell Parish, JD, RAC, CIP, senior regulatory attorney, Quorum IRB

The U.S. Food and Drug Administration (FDA) understands you can’t control absolutely everything posted about your drug or device as part of your effort to solicit new clinical trial subjects, but you’d better keep an eye on promises made regarding how much your product can benefit people. That’s the warning from Mitchell Parish, JD, RAC, CIP, a senior regulatory attorney with Quorum IRB.

FDA also wants you to be proactive when it comes to informed consent and recruitment of potential trial subject, Parish adds. That’s tricky when you go online to find new folks via Facebook and the like. It gets even more troublesome when promises are made or implied that your drug and device can do all sorts of things that don’t strictly adhere to the trial protocol.

It’s critical to have in place a plan to monitor and control, to a realistic extent possible, online chatter about your drug or device, Parish says. For example, FDA will examine whether you encouraged, directly or inadvertently, a comment from someone extolling off-label virtues of the product. It’s also important to remember that product claims require institutional review board review and approval, yet objective information isn’t under the same scrutiny. It’s important to know the difference and have a plan in place with defensible definitions of each, says Parish.

imgOwenGarrick

Owen Garrick, president and chief operating officer, Bridge Clinical Research

Ironically, one of online recruitment’s biggest strengths is also one of its most glaring weaknesses, says Owen Garrick, president and chief operating officer with Bridge Clinical Research. “You see patients and caregivers flocking to social media sites” and willingly sharing information and health tips, he notes. That’s great, but according to Garrick, it also raises thorny questions over how to effectively track promises of efficacy and impact for a drug and device.

“People have become so comfortable sharing that kind of information,” Garrick says. The trouble often begins when patients praise what the drug has done for them personally.

Garrick and Parish will be part of a panel session, Social Media in Clinical Trial Patient Recruitment, at the ACRP 2016 Meeting & Expo in Atlanta, Ga.

Share your thoughts with us!

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s